T-Space at The University of Toronto Libraries >
School of Graduate Studies - Theses >
Please use this identifier to cite or link to this item:
|Title: ||Histone Deacetylase Inhibitor MS-275 Inhibits Neuroblastoma Cell Growth by Inducing Cell Cycle Arrest, Apoptosis, Differentiation and by Targeting its Tumor Stem Cell Population|
|Authors: ||Tsui, Micky Ka Hon|
|Advisor: ||Yeger, Herman|
|Department: ||Laboratory Medicine and Pathobiology|
Histone Deacetylase Inhibitor
cancer stem cell
|Issue Date: ||16-Feb-2010|
|Abstract: ||Objective: MS-275, a phase trialed histone deacetylase inhibitor will be characterized for its ability reduce neuroblastoma (NB) viability and to target the tumor stem cell (TSC) population in neuroblastoma.
Methods: Ability of MS-275 to reduce NB growth is characterized using a tumorigenic NB N-type cell line that has high differentiation potential. TSC enriched side population from NB and a reference teratocarcinoma cell line was analyzed as a model of TSC. The potential of MS-275 to modulate functional characteristics and markers of TSC was also investigated.
Results: MS-275 induces a G1 cell cycle arrest, the intrinsic apoptosis pathway in NB and can potentially differentiate NB into a more terminal phenotype. NB TSC-like population is reduced following MS-275 treatment by the targeting of their self-renewal and drug pumping ability.
Conclusions: By targeting both the NB and its TSC population, MS-275 has therapeutic potential for neuroblastoma. This warrants further in-vivo investigations.|
|Appears in Collections:||Master|
Department of Laboratory Medicine and Pathobiology - Master theses
Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.